News
Lilly to Present New Clinical Data at 75th American Diabetes Association® Scientific Sessions
New clinical data demonstrating the range of treatment options represented in Lilly's diabetes portfolio will be presented in 79 abstracts on June 5-9, at...
Press Releases
U.S. Food and Drug Administration Approves Humalog® 200 units/mL KwikPen®
The U.S. FDA has approved Humalog® 200 units/mL KwikPen, a pre-filled pen containing a concentrated formulation of Lilly's rapid-acting insulin. Humalog®...
Clinical Trials
FDA Approves Addition to CIALIS® (tadalafil) Product Label
Eli Lilly and Company announced the U.S. FDA approved a product label addition for CIALIS to include data from a 26-week study that showed...
Press Releases
Patheon® to Feature API Development and Manufacturing Capabilities at CPhI/ICSE Worldwide
Patheon is to showcase its biologic, small molecule API development services and manufacturing capabilities for finished dosage forms at CPhI / ICSE Worldwide from...
News
Shire open to AbbVie’s upped offer of £31 billion
AbbVie has now laid on the table a bid of £53.20 a share to acquire UK-headquartered Shire, up from last week’s offer of £51.15....
Press Releases
Provepharm¹s Japanese partner Daiichi Sankyo files an NDA to market the Methylene Blue injection medicinal product in Japan
Provepharm, a French company specialized in the development of pharmaceutical applications announces that Daiichi Sankyo, Co. Ltd., a global pharmaceutical firm, has filed an...
Press Releases
Secukinumab showed superiority over Enbrel®
Novartis announced results from the head-to-head Phase III FIXTURE study showing secukinumab an interleukin-17A inhibitor, was significantly superior to Enbrel in moderate-to-severe plaque psoriasis....
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read